Hiort O,Sinnecker GH,Holterhus PM,et al.The clinical and molecular spectrum of androgen insensitivity syndromes[J].Am J Med Genet,1996,63(1):218-222.
[2]
Mendonca BB,Domenice S,Arnhold IJ,et al.46,XY disorders of sex development(DSD)[J].Clin Endocrinol(Oxf),2009,70(2):173-187.
[3]
Ahmed SF,Cheng A,Dovey L,et al.Phenotypic features,androgen receptor binding,and mutational analysis in 278clinical cases reported as androgen insensitivity syndrome[J].J Clin Endocrinol Metab,2000,85(2):658-665.
[4]
He B,Gampe RT Jr,Kole AJ,et al.Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance[J].Mol Cell,2004,16(3):425-438.
[5]
Sanchez D,Rosell D,Honorato B,et al.Androgen receptor mutations are associated with Gleason score in localized prostate cancer[J].BJU Int,2006,98(6):1 320-1 325.
[6]
He B,Gampe RT Jr,Hnat AT,et al.Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity[J].J Biol Chem,2006,281(10):6 648-6 663.
Askew EB,Minges JT,Hnat AT,et al.Structural features discriminate androgen receptor N/C terminal and coactivator interactions[J].Mol Cell Endocrinol,2012,348(2):403-410.
[9]
Askew EB,Gampe RT Jr,Stanley TB,et al.Modulation of androgen receptor activation function 2by testosterone and dihydrotestosterone[J].J Biol Chem,2007,282(35):25 801-25 816.
[10]
He B,Lee LW,Minges JT,et al.Dependence of selective gene activation on the androgen receptor NH2-and COOH-terminal interaction[J].J Biol Chem,2002,277(28):25 631-25 639.
